Clinical Trials
Study shows docetaxel injection with paclitaxel improves breast cancer survival
Published in Women's Health Weekly, September 22nd, 2005
The sanofi-aventis Group announced that the Journal of Clinical Oncology has published the results of a phase 3 trial that demonstrate treatment with Taxotere (docetaxel) Injection Concentrate significantly improved overall survival and median time to disease progression compared with paclitaxel in women with advanced breast cancer whose cancer had progressed after previous treatment with an anthracycline-based therapy.
The study shows a statistically significant median overall survival of 15.4 months for Taxotere versus 12.7 months for paclitaxel (HR, 1.41; 95% CI, 1.15 to 1.73; p=0.03). Taxotere and paclitaxel are agents in a class known as taxanes, which are...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Breast cancer protein biomarkers discovered in studies of blood serum - Cardiovascular Disease
Periodontal disease investigated as precursor of cardiovascular disease - Immunology
Serum acute phase protein concentrations studied after hysterectomy - Pelvic Pain
Study: UPLIFT procedure reduces pelvic pain caused by a tipped uterus - Uterine Cancer Treatment
Topotecan evaluated for treatment of uterine carcinosarcoma - Breast Cancer
Age a factor in breast cancer risk with previous oral contraceptive use - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
